Century Therapeutics (IPSC) Amortization of Deferred Charges (2020 - 2023)

Century Therapeutics (IPSC) has 4 years of Amortization of Deferred Charges data on file, last reported at $38000.0 in Q2 2023.

• On a quarterly basis, Amortization of Deferred Charges fell 50.0% year-over-year to $38000.0 in Q2 2023; TTM through Dec 2023 was $94000.0, a 68.46% decrease from a year earlier, with the FY2023 full-year figure at $94000.0, down 68.56% from the prior year.
• Amortization of Deferred Charges for Q2 2023 stood at $38000.0, down from $56000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for IPSC reached as high as $78000.0 in Q4 2020 and fell as low as $14000.0 in Q3 2020.
• Historically, Amortization of Deferred Charges has averaged $65750.0 across 4 years, with a median of $76000.0 in 2021.
• Across the five-year window, Amortization of Deferred Charges soared 450.0% in 2021 and slumped 50.0% in 2023, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $78000.0 in 2020, then decreased by 1.28% to $77000.0 in 2021, then decreased by 10.39% to $69000.0 in 2022, then tumbled by 44.93% to $38000.0 in 2023.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $38000.0 in Q2 2023, $56000.0 in Q1 2023, and $69000.0 in Q4 2022.